Ieq Capital LLC Has $2.88 Million Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

Ieq Capital LLC grew its holdings in Twist Bioscience Co. (NASDAQ:TWST) by 21.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 62,034 shares of the company’s stock after purchasing an additional 10,800 shares during the period. Ieq Capital LLC’s holdings in Twist Bioscience were worth $2,883,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in TWST. Massachusetts Financial Services Co. MA increased its stake in Twist Bioscience by 215.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock valued at $1,324,000 after buying an additional 20,035 shares during the last quarter. Barclays PLC grew its holdings in shares of Twist Bioscience by 214.8% in the 3rd quarter. Barclays PLC now owns 153,039 shares of the company’s stock valued at $6,913,000 after acquiring an additional 104,420 shares in the last quarter. FMR LLC increased its position in shares of Twist Bioscience by 6.0% in the third quarter. FMR LLC now owns 218,561 shares of the company’s stock valued at $9,875,000 after acquiring an additional 12,327 shares during the last quarter. Avanza Fonder AB bought a new stake in Twist Bioscience during the fourth quarter worth about $1,059,000. Finally, BNP Paribas Financial Markets boosted its position in Twist Bioscience by 128.1% during the third quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock valued at $1,718,000 after purchasing an additional 21,357 shares during the last quarter.

Analyst Ratings Changes

Several research analysts have weighed in on TWST shares. JPMorgan Chase & Co. boosted their price target on Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 4th. Barclays set a $58.00 price target on shares of Twist Bioscience and gave the stock an “overweight” rating in a research report on Monday, February 3rd. Scotiabank reissued an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. TD Cowen restated a “buy” rating and set a $58.00 price objective on shares of Twist Bioscience in a research note on Tuesday, November 26th. Finally, Robert W. Baird raised their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research note on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, Twist Bioscience presently has a consensus rating of “Moderate Buy” and a consensus target price of $54.40.

Twist Bioscience Stock Performance

Shares of TWST stock opened at $41.31 on Friday. Twist Bioscience Co. has a 52 week low of $27.41 and a 52 week high of $60.90. The company has a market capitalization of $2.46 billion, a price-to-earnings ratio of -12.22 and a beta of 1.87. The company has a 50-day simple moving average of $48.10 and a 200 day simple moving average of $45.75. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. During the same quarter in the previous year, the company posted ($0.75) earnings per share. The business’s revenue was up 24.1% on a year-over-year basis. On average, sell-side analysts predict that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, Director Robert Chess sold 3,504 shares of Twist Bioscience stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $51.85, for a total value of $181,682.40. Following the completion of the sale, the director now owns 21,641 shares in the company, valued at $1,122,085.85. The trade was a 13.94 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Emily M. Leproust sold 2,216 shares of the stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $52.70, for a total transaction of $116,783.20. Following the transaction, the chief executive officer now owns 674,718 shares in the company, valued at approximately $35,557,638.60. The trade was a 0.33 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 37,180 shares of company stock worth $1,821,971 in the last ninety days. 3.01% of the stock is owned by company insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.